Patent

Should Patents Create Incentives for Failure?

Should Patents Create Incentives for Failure?

One scholar argues that patents do not—and should not—compensate for the costs of drug development.

Challenging Drug Patents to Lower Prices

Challenging Drug Patents to Lower Prices

The FTC cracks down on improperly listed drug patents, challenging over 100 patent listings.

How Patents Contribute to High Drug Prices

How Patents Contribute to High Drug Prices

Patents covering drugs selected for Medicare price negotiation show how patents influence drug prices.

Oh, When the Feds Go Marching-In

Oh, When the Feds Go Marching-In

Marching-in could allow federal government to commercialize inventions, but at the expense of patent rights.

Headless Agency Adjudication at the Patent Office

Headless Agency Adjudication at the Patent Office

Supreme Court approval of patent adjudication raises new questions about limits of modern agency adjudication.

The First Amendment Protects Offensive Trademarks

The First Amendment Protects Offensive Trademarks

Supreme Court holds that government cannot discriminate against offensive trademarks.

For Hepatitis Drugs, Availability Does Not Equal Access

For Hepatitis Drugs, Availability Does Not Equal Access

Is the government willing to infringe on drug patents to curb a public health crisis?

Simplicity Trumps Logical Coherence

Simplicity Trumps Logical Coherence

The Supreme Court upholds its concededly “incorrect” ban on post-expiration patent royalties.

Chevron Deference for the U.S. Patent and Trademark Office

Chevron Deference for the U.S. Patent and Trademark Office

Asymmetrical deference to PTO decision-making may promote pro-patent policies.

Unmasking Patent Trolls

Unmasking Patent Trolls

Patent and Trademark Office proposes rule that would seek to increase transparency in patent ownership.

Evaluating the PTO’s Proposed Fee Structure

Evaluating the PTO’s Proposed Fee Structure

Proposed fee structure remains flawed and may contribute to the perception of a “broken” patent system.